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Abstract: 
 
Aim: Fungi are valuable resources for bioactive secondary metabolites. However, the chemical 
space of fungal secondary metabolites has been studied only on a limited basis. Herein, we report 
a comprehensive chemoinformatic analysis of a unique set of 207 fungal metabolites isolated and 
characterized in a USA National Cancer Institute funded drug discovery project.  
 
Results: Comparison of the molecular complexity of the 207 fungal metabolites with approved 
anticancer and nonanticancer drugs, compounds in clinical studies, general screening compounds 
and molecules Generally Recognized as Safe revealed that fungal metabolites have high degree 
of complexity. Molecular fingerprints showed that fungal metabolites are as structurally diverse 
as other natural products and have, in general, drug-like physicochemical properties.  
 
Conclusion: Fungal products represent promising candidates to expand the medicinally relevant 
chemical space. This work is a significant expansion of an analysis reported years ago for a 
smaller set of compounds (less than half of the ones included in the present work) from 
filamentous fungi using different structural properties. 
 
Keywords: chemical space | chemoinformatics | fungal metabolites | master key compound | 
molecular complexity | molecular fingerprint 
 
Article: 
 
Introduction 
 
Natural products are important sources for new drugs and are also good lead compounds suitable 
for further optimization. The pharmaceutical industry has obtained many successful leads from 
natural sources. Approximately 45% of today's best selling drugs are either natural products or, 
more typically, their semisynthetic derivatives [1]. This could be because natural products have 
some important advantages over synthetic compounds: their biosynthesis involves repetitive 
interactions with enzymes, and for most of them, their actual biological function likely relies 
upon the ability to bind to proteins. This may explain why secondary metabolites exhibit 
advanced binding characteristics compared with synthetic compounds [2]. The chemical space of 
natural products (largely derived from plants), their synthetic derivatives and approved drugs 
from natural origin has been extensively explored. From such studies it has been concluded that, 
in general, natural products have larger size, greater 3D complexity, lower hydrophobicity, 
increased polarity and fewer aromatic rings than other compound libraries [3]. 
 
Most natural product-derived leads come from plant or microbial sources. There are also a few 
remarkable drugs from marine sources, such as the recently approved anticancer drug eribulin, a 
synthetic analog of halichondrin B isolated from the sponge Halichondria okadai [4]. In the 
microbial area the main sources have been terrestrial actinomycetes and fungi. From the latter, 
the secondary metabolite myriocin was the base for the development of fingolimod as the first 
oral orally active drug for multiple sclerosis. 
 
 
Figure 1. Representative examples of fungal metabolites as drugs. 
 
Out of the estimated 1.5–5.5 million species of fungi in the world, only approximately 75,000–
100,000 species have been described, and yet, fungi from many different sources continue to be a 
valuable resource of bioactive secondary metabolites such as antibiotics (cephalosporin), 
immunosuppressants (cyclosporine A), cholesterol-lowering agents (statins), antifungals 
(echinocandin B), for the treatment of multiple sclerosis (fingolimod), anticancer drugs 
(lentinan), for the treatment of hemorrhage (methergin) and fungicides (strobilurins). Figure 
1 shows remarkable examples of fungal metabolites (or synthetic analogues) used as drugs [5]. 
Since there are many unexplored fungal species, there is a high probability for discovering new 
lead structures. However, the chemical space of secondary metabolites isolated from fungi has 
been studied only on a limited basis. 
 
An initial effort to explore the chemical space of fungal isolates was reported by El-Elimat et al. 
[6]. In that work, 105 compounds isolated from filamentous fungi, 75 from cyanobacteria and 
163 compounds from tropical plants were compared with each other, and to 96 US FDA-
approved anticancer drugs, using nine molecular descriptors. Data visualization was conducted 
using principal component analysis. It was concluded that anticancer drugs cover a large fraction 
of biologically active chemical space, and that the set of fungal metabolites had a high overlap 
with the chemical space of anticancer drugs. A reasonable explanation for the high overlap was 
that 59% of the anticancer drugs were either natural products or compounds derived and/or 
inspired by them. However, given the limited number of fungal metabolites that have been tested 
in anticancer assays, this was an encouraging finding. It was also noted that the secondary 
metabolites isolated from each source represented different areas of chemical space, and 
therefore, the collective study of each natural source has cumulative benefits toward probing 
chemical diversity. 
 
Based on previous studies and as part of our continued effort to quantify the chemical diversity 
of fungal isolates [6], herein we expand the analysis to a larger set of 207 compounds described 
by our group [7–23] that represent twice the size of the dataset analyzed in 2012. In the current 
analysis, we employed molecular fingerprints as distinct molecular representations not analyzed 
in the previous study; also we emphasized the evaluation of molecular complexity that may have 
a significant impact in drug discovery endeavors, since this feature has been associated with 
target selectivity (and potential toxicity). As part of the analysis, we implemented a novel 
consensus measure of structural complexity. The chemical space and structural diversity of the 
fungal isolates were compared with anticancer and nonanticancer approved drugs, other 
reference datasets of pharmaceutical interest, and a unique dataset of Generally Recognized as 
Safe (GRAS) compounds used in the food industry [24]. 
 
Methods 
 
General approach 
 
The compound datasets were analyzed using validated chemoinformatics methods to characterize 
compound libraries [25–27]. Chemoinformatic-based analysis of compound libraries is part of 
the preliminary characterization of datasets used for drug discovery, providing key information 
to characterize molecular diversity and coverage of chemical space [28]. Of note, in the study 
published in 2012 for a smaller (105) set of compounds, nine molecular descriptors commonly 
used in compound characterizations were computed [6]. Herein, for the 207 fungal metabolites 
we included a number of previously computed properties plus a novel set of descriptors that 
capture different aspects of the molecules. 
 
Datasets 
 
Table 1 summarizes the datasets used, including the number of unique compounds after data 
curation. In total, 5494 compounds were analyzed. Prior to analysis, all datasets were curated 
using Molecular Operating Environment, version 2014.08 [29]. Molecules were washed using a 
protocol implemented in Molecular Operating Environment that involves removing salts and 
neutralizing the charges in the molecules. The largest fragments were kept, duplicates in each 
dataset were removed and all molecules with molecular weight (MW) over 1000 were excluded. 
The in-house library of fungal metabolites with 207 compounds (referred to hereafter as 
‘FUNGI’) [7–23] was compared with the following five reference collections: 2249 compounds 
based on the Flavor and Extract Manufacturers Association of the United States GRAS list, 
updated to GRAS 27 (hereafter referred to as ‘GRAS’) [24,30]; FDA drugs obtained from 
DrugBank [31] containing: 76 drugs approved to treat cancer (hereafter referred to as ‘FDA-
ONC’) and 1399 nononcological drugs (hereafter referred to as ‘FDA-NONC’); 713 drugs in 
clinical trials reported by the Therapeutic Target Database [32] (hereafter referred to as 
‘CLINIC’); and 850 compounds from a commercial collection focused on epigenetic targets, 
available at Selleckchem (hereafter referred to as ‘GENERAL’) [33]. Supplementary Table 
1 summarizes the number of duplicate molecules found in the initial datasets. The chemical 
structures of representative fungal metabolites analyzed in study are shown in Supplementary 
Figure 1. The full dataset of fungal metabolites is available upon request. 
 
Table 1. Compound datasets considered in this work. 
Dataset Initial size Unique compounds 
Fungal isolates (FUNGI)  224 207 
Approved anticancer drugs (FDA-ONC) 82 76 
Approved nonanticancer drugs (FDA-NONC) 1536 1399 
Drugs in clinical trials (CLINIC) 832 713 
General screening collection (GENERAL) 1094 850 
Generally Recognized as Safe (GRAS) 2295 2249 
 
Molecular representations 
 
To reduce the dependence of chemical space with structure representation, we used different 
representations. These can be classified into three main groups: molecular complexity, structural 
fingerprints and physicochemical properties. 
 
Molecular complexity 
 
Three measures were used to compare the structural complexity of the datasets: fraction of 
sp3 carbon atoms (F-sp3), fraction of chiral centers (CCF) and globularity (GLOB). F-sp3 and 
CCF are complexity metrics that have been used broadly to measure MC [34,35]. A higher value 
of CCF means higher stereochemical complexity and a larger F-sp3 value indicates that the 
molecule is more likely to have a 3D structure, in other words, a nonplanar structure. 3D 
structures are preferred over planar structures with the hypothesis that molecules with out-of-
plane substituents could adjust their molecular shape and increase receptor/ligand 
complementarity [34]. However, only considering sp3 carbons may not be enough to determine if 
a molecule has a 3D structure: F-sp3 does not account for 3D structures given by sp3-hybridized 
heteroatoms. However, GLOB does capture this structural feature. GLOB evaluates the 
resemblance of a compound to a sphere, a value equal to 1 represents a spherical molecule while 
a value equal to 0 represents a structure that is completely flat. F-sp3 was computed with Maya 
ChemTools [36], dividing the number of sp3 hybridized carbons by the total carbon count; CCF 
was calculated using Molecular Operating Environment software dividing the number of chiral 
centers (ChC) by the total carbon count. GLOB was calculated with Molecular Operating 
Environment software using the conformation with a low-energy conformation. The distributions 
of the F-sp3, GLOB and CCF values were analyzed using box plots. The statistical analysis of the 
distributions of F-sp3, GLOB and CCF was done with R Studio [37]. The statistical comparison 
of the complexity measures was made by the assessment of the homoscedasticity with a Shapiro 
test in which a normal distribution may be assumed if a p-value >0.05 is obtained. In order to do 
pairwise comparisons, a Kruskal–Nemenyi test was performed, for which a p-value <0.05 
indicates that the null hypothesis must be accepted, meaning that there is not a statistically 
significant difference between the distributions in the datasets. All the statistics were generated 
with R Studio using the PMCMR package. In addition, we computed the mean complexity (MC) 
as the mean of F-sp3, GLOB and CCF values. MC represents a combined measure of MC. For 
each dataset, the distribution of MC values was obtained along with the corresponding summary 
statistics. In an attempt to determine whether differences could be observed when considering the 
total number of heavy atoms (HAs) or MW to calculate the fraction of sp3 carbon atoms, 
molecular globularity and CCF, we calculated six related fractions: sp3/MW, ChC/MW, sp3/HA, 
ChC/HA, GLOB/MW and GLOB/HA. An MC of the fractions normalized with MW (MCMW) 
and an MC for the fractions normalized with HA (MCHA) were calculated for each dataset. The 
statistical analysis between datasets was generated with R Studio as described for each metric of 
molecular complexity. 
 
Structural fingerprints 
 
Two structural fingerprints of different design: Molecular ACCess System (MACCS) keys (166-
bits) [38] and extended connectivity fingerprints, ECFP4 (ECFPs) [39]. The distribution of the 
similarity values was analyzed by cumulative distribution functions (CDF) generated with 
MayaChem Tools and R Studio scripts. 
 
Physicochemical properties 
 
Six properties were calculated with Molecular Operating Environment software. Hydrogen bond 
donors (HBDs), hydrogen bond acceptors (HBAs), the octanol and/or water partition coefficient 
(SlogP) and MW; these physicochemical properties are associated with solubility and 
permeability. Topological polar surface area (TPSA), an important parameter related to 
solubility, permeability and transport of a compound; and number of rotatable bonds, which is an 
indicator of the flexibility of the molecules. For each database and property, a box plot was 
generated. The statistical comparison of the properties was made with R Studio as described in 
the ‘Methods’ section. To generate a visual representation of the chemical space based on 
physicochemical properties, a principal component analysis was performed with the six 
physicochemical properties using DataWarrior, version 4. 2. 2 [40]. 
 
Results & discussion 
 
 
Figure 2. Molecular complexity of fungal isolates. 
Box plots of the distributions of CCF, F-sp3 and globularity for the fungal isolates, molecules Generally 
Recognized as Safe, US FDA-approved drugs to treat cancer, FDA-approved drugs, drugs in clinical trials and 
compounds from a screening collection. Summary statistics are shown below each box plot. See text for details. 
1st Q: First quartile; 3rd Q: Third quartile; CCF: Fraction of chiral centers; CLINIC: Drugs in clinical 
trials; FDA-NONC: FDA-approved drugs; FDA-ONC: FDA-approved drugs to treat cancer; FUNGI: Fungal 
isolates; F-sp3: Fraction of sp3 carbon atoms; GENERAL: Compounds from a screening collection; GLOB: Fraction 
of globularity; GRAS: Generally Recognized as Safe. 
 
Structural complexity 
 
Many drug discovery efforts focus on compound libraries containing small molecules filtered 
using classical semi-empirical rules. Filtered molecules often interrogate a narrow range of 
medicinal chemical space but have failed to identify leads for many target classes [41]. Structural 
complexity is an attractive criterion for the drug discovery process. Indeed, previous studies have 
shown that increased structural complexity, as measured by simple metrics such as F-sp3 and 
CCF, is associated with increased probability to reach the market and 3D structures that might 
allow additional protein–ligand interactions not accessible to a flat aromatic ring [34]. 
Furthermore, preliminary experimental analyses have shown that increased structural complexity 
is related to target selectivity [35]. Therefore, we measured the distribution of the structural 
complexity of the 207 fungal metabolites using Fsp3 and CCF, previously studied metrics. 
GLOB was also included as an approach to obtain a more accurate description of the molecules 
shape and 3D structure. A consensus measure of complexity with these three descriptors was 
introduced and the results were compared with the reference collections. Of course, additional 
metrics to measure structural complexity could be used [42,43]. Figure 2 shows box plots of the 
distribution of CCF, GLOB and F-sp3along with summary statistics. Supplementary Table 
3 shows the Kruskal–Nemenyi test results for the complexity analysis. 
 
The CCF and F-sp3 values for the FDA-NONC compounds (that represent a larger fraction of all 
the FDA-approved compounds) are larger and statistically different from the CLINIC set (Figure 
2 & Supplementary Table 2). In general, considering Fsp3 and CCF, the FDA-approved drugs 
and CLINIC are more complex than the GENERAL screening collection. Indeed, considering the 
FDA-approved drugs as a single compound set, the relative order of structural complexity 
decreases in the order Drugs (both FDA categories) > CLINIC > GENERAL which is in good 
agreement with previously reported data [34]. Interestingly, 3D measured with GLOB shows that 
FDA-ONC, GENERAL and CLINIC are not statistically different. 
 
Impressively, FUNGI showed larger and statistically different CCF values than all reference 
datasets, including FDA-approved drugs and in particular FDA-ONC. FUNGI had similar F-
sp3 and GLOB values as FDA-NONC, and both datasets exhibited higher values than FDA-
ONC. Compared with GENERAL, FUNGI showed larger values of F-sp3, GLOB and CCF, 
demonstrating their increased structural complexity as compared with molecules typically used 
in high-throughput screening. 
 
Interestingly, GRAS compounds had the largest structural complexity as measured by the 
distribution of F-sp3 values (Figure 2). This intriguing result and the inherent safety of GRAS 
chemicals for human consumption (at given doses) is in agreement with the general notion that 
large structure complexity can be associated with selectivity, and possibly, less toxicity [34]. The 
hypothesis of a putative correlation between compound safety and structural complexity is being 
fully evaluated in our group and will be reported in a separate work (see the ‘Future perspective’ 
section). An unexpected finding was that, even though GRAS has the highest F-sp3 values, it also 
has one of the lowest GLOB values. This is in agreement with the hypothesis that sp3-hybridized 
heteroatoms should be considered to study the complexity and 3D structure of molecules. 
 
Combined measure of complexity 
 
A simple aggregated measure of MC was obtained by computing the mean of F-sp3, GLOB and 
CCF (see the ‘Methods’ section). Figure 3 shows the distribution of the MC values for each 
dataset. Supplementary Table 2 summarizes the Kruskal–Nemenyi test results. According to this 
aggregated measure of complexity, FUNGI were statistically more complex than CLINIC, 
GENERAL and FDA-approved drugs, in particular FDA-ONC. Interestingly, according to MC, 
GRAS was not statistically different from FUNGI (Supplementary Table 2). Consistent with 
other metrics, the GENERAL set was the least complex. Finally, on average, the FDA-NONC 
and the FDA-ONC datasets showed a different degree of complexity as captured by MC values. 
This suggests that complexity among approved drugs can be significantly different depending on 
the therapeutic indication. 
 
 
Figure 3. Box plot and summary statistics of the mean of F-sp3, fraction of chiral centers and 
globularity or mean complexity. 
See text for details. 
1st Q: First quartile; 3rd Q: Third quartile; CCF: Fraction of chiral centers; F-sp3: Fraction of sp3 carbon 
atoms; GLOB: Fraction of globularity. 
 
Figure 4 shows the mean of Fsp3 and FCC values mapped on a visual representation of the 
chemical space generated with principal component analysis of six physicochemical properties: 
HBA, HBD, SlogP, TPSA, MW and RB (see the ‘Profile of physicochemical properties’ 
section). A color scale was implemented to highlight each data point using MC in which the 
most complex compounds were marked red, the moderately complex compounds yellow and the 
less complex compounds were marked green. Based on the colors, the GRAS database contains 
more yellow-to-red colored molecules when compared with GENERAL where most of the 
molecules are green. This visualization was in line with the MC metric (in Figure 3) in which 
GENERAL was the least complex collection. The FUNGI dataset contained fewer molecules 
than GENERAL (Table 1), but based on the color scale, most of the molecules were orange-to-
red indicating high complexity. The distribution of each dataset in the chemical space based on 
the physicochemical properties is discussed in the ‘Profile of physicochemical properties’ 
section. 
 
 
Figure 4. Visualization of the molecular complexity mapped on a representation of the chemical 
space generated with principal component analysis of six physicochemical properties. 
The first two principal components recover 85% of the variance. Data points are colored by the mean of 
Fsp3and FCC using a continuous color scale from green (less complex) to red (more complex). Each panel 
corresponds to the visualization of single datasets. 
CLINIC: Drugs in clinical trials; FCC: Fraction of chiral centers; FDA-NONC: FDA-approved drugs; 
FDA-ONC: FDA-approved drugs to treat cancer; FUNGI: Fungal isolates; F-sp3: Fraction of sp3 carbon atoms; 
GENERAL: Compounds from a screening collection; GLOB: Fraction of globularity; GRAS: Generally Recognized 
as Safe; PC: Principal component. 
 
FUNGI and the reference sets were compared using the MCHA and MCMW metrics (see the 
‘Methods’ section). The goal was to explore the effects of different approaches to normalize the 
number of sp3 carbon atoms and ChC on the relative order of MC of the datasets. The 
corresponding box plots and summary statistics of the distributions of MCHA and MCMW are 
in Supplementary Figure 2. Overall, considering the different normalization methods, similar 
conclusions were obtained regarding the relative MC of FUNGI compared with the reference 
datasets. GRAS showed an increased MC, and was statistically more complex than the other 
datasets. 
 
The analysis of MC supported the hypothesis that fungal metabolites are remarkable candidates 
to expand the medicinally relevant chemical space [41]. The profile of stereochemical 
complexity and 3D character (nonflat structures) makes fungal metabolites attractive compounds 
as drug sources with the potential to be selective and likely to succeed as future drugs [34]. Of 
note this is the first study that quantifies directly the structural complexity of fungal metabolites. 
 
Structural diversity using molecular fingerprints 
 
 
Figure 5. Molecular diversity of the fungal metabolite dataset and reference collections. 
This figure shows the cumulative distribution functions of all pair-wise similarity comparisons using the 
Tanimoto coefficient using Molecular ACCess System keys. The table summarizes the summary statistics of the 
cumulative distribution functions. The FUNGI set was less diverse than GRAS, US FDA, CLINIC and GENERAL 
but is as diverse as other natural product datasets reported in the literature [41,46]. 
1st Q: First quartile; 3rd Q: Third quartile; CLINIC: Drugs in clinical trials; FDA-NONC: FDA-approved 
drugs; FDA-ONC: FDA-approved drugs to treat cancer; FUNGI: Fungal isolates; F-sp3: Fraction of sp3 carbon 
atoms; GENERAL: Compounds from a screening collection; GLOB: Fraction of globularity; GRAS: Generally 
Recognized as Safe; MACCS: Molecular ACCess System. 
 
As discussed in the ‘Introduction’ section, this is the first report that addresses in a quantitative 
manner the structural diversity of fungal metabolites using molecular fingerprints. The structural 
diversity of each dataset was also measured computing all possible pair-wise comparisons with 
the Tanimoto coefficient [44,45] and two fingerprint-based structure representations: MACCS 
keys and ECFPs, previously described in the ‘Methods’ section. The Tanimoto coefficient 
measures the ratio of the set of structural features that two compounds have in common with 
respect to the total structural features of both compounds (as codified by the corresponding 
fingerprint representation). Figure 5 shows the CDF curves (along with summary statistics) of 
the pair-wise similarity values for each dataset using MACCS keys. The CDF curves of ECFPs 
are shown in Supplementary Figure 3. 
 
Analysis of the CDF indicated that the FUNGI set was diverse with, for instance, median 
MACCS/Tanimoto similarity of 0.52 (and median of 0.143 with ECFP). Despite the fact that the 
FUNGI set showed the lowest structural diversity as compared with the other collections studied 
in this work (e.g., the intralibrary similarity was higher, Figure 5), their diversity was comparable 
(calculated using the same metrics) to other natural products such as molecules from traditional 
Chinese medicine or a dataset of commercially available natural products for high-throughput 
screening [41,46]. 
 
Out of the datasets compared in this work, FDA-NONC was the most diverse followed by GRAS 
and compounds in the GENERAL and CLINIC datasets. Overall, the similarity values for the 
reference datasets were consistent with the values reported in the literature. The FDA-ONC set 
had higher similarity values compared with the values reported for approved drugs [41]. This 
result can be explained because FDA anticancer drugs are focused on fewer molecular targets 
and occupy a narrower (focused) region of the drug-like chemical space. 
 
Profile of physicochemical properties 
 
In addition to measuring structural complexity and molecular diversity using structural 
fingerprints, we also obtained the physiochemical profile of the FUNGI set. This is because in 
library selection and design it is important to have a balance between the structural diversity and 
physicochemical drug likeness [47]. As mentioned in the ‘methods’ section, six physicochemical 
properties of pharmaceutical relevance were analyzed for the 207 fungal metabolites and the 
reference datasets. Box plots and summary statistics of the six properties for all collections are 
shown in Supplementary Figure 4 & Supplementary Table 1 . 
 
TPSA is an important parameter for the permeability, solubility and transport of compounds 
[48]. The FUNGI set had comparable values of TPSA with FDA-ONC. Indeed, it has been 
suggested that TPSA is one of the key physicochemical properties that confer the drug-likeness 
character to natural products [49]. 
 
Regarding molecular flexibility as measured by RB, the FUNGI set was similar to GRAS, and 
both sets were less flexible than FDA-approved drugs, CLINIC and GENERAL datasets. The 
fungal metabolites analyzed in this work were not statistically different from FDA-ONC in terms 
of HBA, HBD and MW. This result is in line with the conclusions obtained in the previous work 
for a smaller set of fungal metabolites described in the ‘Introduction’ section. [6]. 
 
Figure 6. 3D and 2D visual representation of the chemical space of 207 fungal isolates 
considered in this work. 
The visual representation was generated with a principal component analysis of six physicochemical 
properties: molecular weight, hydrogen bond donors, hydrogen bond acceptors, the octanol and/or water partition 
coefficient, topological polar surface area and number of rotatable bonds. The first two principal components 
capture 85.2% of the variance and the first three principal components capture 93.9% of the variance. FUNGI: 
purple; GRAS: yellow; FDA-ONC: green; FDA-NONC: red; CLINIC: blue; GENERAL: turquoise. 
 
It is noteworthy that there was a statistical difference between the datasets with FDA-approved 
drugs; on average FDA-ONC drugs had higher values than FDA-NONC for most of the 
computed properties. In other words, there is a considerable difference in the physicochemical 
properties of drugs used to treat cancer and drugs approved for other indications. 
 
2D and 3D visual representations of the chemical space based on the six properties are shown 
in Figure 6. The first two principal components retrieved 85.2% of the variance, whereas 93.9% 
was recovered by using the first three principal components. Supplementary Table 5 summarizes 
the loadings for the six properties. Supplementary Table 5 indicates that HBA and HBD had the 
highest contributions to the first principal component, SlogP had the highest contribution to the 
second principal component and RB had the highest contribution to the third principal 
component. Figure 6 shows that fungal metabolites cover similar regions of the property space of 
FDA-approved drugs, CLINIC and GENERAL, particularly FDA-ONC. This result was 
consistent with the conclusions obtained in our previous work [6]. Interestingly, most of the 
outliers were either molecules with many ChC, or highly saturated molecules. As expected, most 
of the molecules in FDA-ONC, GENERAL and CLINIC occupy similar regions of the chemical 
space, indicating that these sets have, in general, comparable physicochemical properties (as 
quantitatively captured by the box plots in Supplementary Figure 4). 
 
FDA-NONC compounds showed a broader coverage of the property space. Interestingly, GRAS 
molecules occupy a well-defined and distinct area of the space that was associated with the 
smallest molecules. In fact, based on the distribution of the physicochemical properties and 
visual representation of the chemical space, GRAS molecules were, overall, smaller molecules 
than the other reference collections. However, GRAS compounds have comparable SlogP values. 
Of note, the octanol/water partition coefficient is one of the most important drug-like 
physicochemical properties [49]. Fungal metabolites share pharmaceutical important 
physicochemical properties with the approved drugs. Even though natural products do not 
necessarily follow all Lipinski's Rule of Five [49], in general, the fungal isolates studied in this 
work fulfilled those rules. 
 
Conclusion 
 
In this work, we quantified for the first time the structural complexity of 207 fungal natural 
products previously isolated and characterized during our investigation into cytotoxic fungal 
metabolites conducted over the past decade. It was concluded that the chemical structures of 
fungal metabolites are more complex than FDA-approved drugs, compounds undergoing clinical 
trials and general screening molecules. This distinct feature of fungal metabolites, combined with 
similar structural diversity compared with other natural products datasets, quantified using 
several molecular fingerprints and drug-like physicochemical properties make fungal metabolites 
an attractive source to cover novel regions of the medicinally relevant chemical space. During 
the course of this study, differences in the structural complexity and physicochemical profile of 
FDA-approved anticancer and nonanticancer drugs were evaluated. Interestingly, GRAS 
compounds had the highest MC profile as measured by the fraction of sp3 carbon atoms. This 
result led to the hypothesis that MC could be related to compound safety, in other words, low 
toxicity. However, considering the mean of F-sp3, GLOB and CCF as a simple measure of 
complexity, a similar profile of MC of fungal metabolites and GRAS molecules was observed. 
This result suggested that both types of structures have the potential to present similar target 
selectivity profiles. Taking all results together, it can be concluded that the fungal metabolites are 
attractive sources of leads, likely because they combine high complexity and structural diversity 
with drug-like physicochemical properties. 
 
Future perspective 
 
The long-term goal of this study is to contribute to the systematic identification of bioactive 
compounds from fungi. This plan is in agreement with an effort to synergize natural product-
based and computer-aided drug discovery [50]. One of the first steps to systematically identify 
active molecules in compound libraries is to characterize the chemical space. However, only few 
reports of efforts to characterize the chemical space of fungal metabolites have been published. 
To our knowledge, this is the second computational study that expands the findings of our work 
published 4 years ago for a smaller set of fungal metabolites (with half of the molecules 
reported) using different metrics and structure representations. Therefore, it is expected that this 
study will continue to stimulate the research community, including our own groups, by 
expanding our knowledge of the chemical space of fungal metabolites. Moreover, the findings of 
this Short Communication led to hypotheses that warrant further computational and experimental 
exploration. At least three follow-up studies can be envisioned: experimental testing of fungal 
metabolites across different molecular targets. In addition to uncovering new bioactive leads, 
results of the screening will test the hypothesis that the large structural complexity of fungal 
metabolites is associated with target selectivity. Computational and experimental assessment of 
the putative association between compound toxicity with MC, and target fishing, in other words, 
computational prediction of molecular targets of fungal metabolites followed by rigorous 
experimental validation. 
 
Executive summary 
 
• Fungal metabolites have high structural complexity, large structural diversity 
(comparable to other natural products) and drug-like physicochemical properties. 
Therefore, they are attractive compounds to expand the medicinally relevant chemical 
space. 
• Findings of this work led to the hypothesis that fungal metabolites have, in general, a 
promising potential to be selective if tested across diverse molecular targets. Future 
systematic experimental screening will test this hypothesis. 
• Generally Recognized as Safe compounds had larger structural complexity than approved 
drugs and fungal metabolites. Hence, it is hypothesized that molecular complexity can be 
associated with compound safety, in other words, low toxicity. This hypothesis is 
currently being tested by our group. 
• Notable differences were found between the chemical space of approved oncological and 
nononcological drugs. 
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